May 16, 2019 10:29 AM EDT
News Briefing

Ab­b­Vie/Roche's Ven­clex­ta wins fourth ap­proval; WuXi, fel­low CRO Al­ta­sciences ink deal

Natalie Grover

Reporter

→ Ab­b­Vie and Roche’s blood can­cer drug, Ven­clex­ta, has notched a fourth ap­proval. On Wednes­day, Ab­b­Vie $AB­BV said the drug was ap­proved in com­bi­na­tion with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times